Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sekur Private Data Advances Defense-Grade Secure Communications Platform (click to learn more) Explore the Innovation Trends Shaping Tomorrow’s Investment Landscape (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Bioatla Inc BCAB

Healthcare Biotechnology
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung... see more

Current News (NDAQ:BCAB)

BioAtla Announces Share Consolidation

GlobeNewswire March 31, 2026

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

GlobeNewswire March 31, 2026

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

GlobeNewswire March 2, 2026

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire December 31, 2025

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

GlobeNewswire November 21, 2025

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

GlobeNewswire November 13, 2025

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

GlobeNewswire November 7, 2025

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

GlobeNewswire November 5, 2025

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

GlobeNewswire October 23, 2025
View More News ››

Opinion & Analysis (NDAQ:BCAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BCAB)

Be the first to post on this bullboard.

US Energy Corp

US Energy Corp

U.S. Energy Corp., an independent energy company, focuses on the acquisition, exploration, and development of industrial gas, ...
View More »

Podcasts